Vasomune Therapeutics and AnGes signed an innovative global Co-Development Agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization.  The collaboration is designed to advance Vasomune’s peptide-based Tie2 receptor agonist program, initially for the treatment of critical care indications, including Acute Respiratory Distress Syndrome (“ARDS”), into clinical development.  ARDS is a critical care indica...